Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 19:21 ET | Source: Cellectis Inc.

Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...
March 19, 2026 19:21 ET | Source: Cellectis Inc.

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...
March 12, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026

NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome...
March 12, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
March 12, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal...
March 12, 2026 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided...
March 04, 2026 16:30 ET | Source: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 04 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
March 04, 2026 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, March 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
March 02, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
February 18, 2026 11:04 ET | Source: Research and Markets

CAR T - Cell Therapy Competitive Landscape Research Report 2026: Comprehensive Insights About 250+ Companies and 500+ Drugs - Key Opportunities Lie in Targeting Hematologic Malignancies

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CAR T - Cell Therapy - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive...